Literature DB >> 33020596

Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study.

Charlie N Saunders1, Alex J Cornish2, Ben Kinnersley2, Philip J Law2, Richard S Houlston2.   

Abstract

BACKGROUND: The aetiology of glioma is poorly understood. Summary data from genome-wide association studies (GWAS) can be used in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to search for glioma risk factors.
METHODS: We performed an MR-PheWAS analysing 316 phenotypes, proxied by 8387 genetic variants, and summary genetic data from a GWAS of 12,488 glioma cases and 18,169 controls. Causal effects were estimated under a random-effects inverse-variance-weighted (IVW-RE) model, with robust adjusted profile score (MR-RAPS), weighted median and mode-based estimates computed to assess the robustness of findings. Odds ratios per one standard deviation increase in each phenotype were calculated for all glioma, glioblastoma (GBM) and non-GBM tumours.
RESULTS: No significant associations (P < 1.58 × 10-4) were observed between phenotypes and glioma under the IVW-RE model. Suggestive associations (1.58 × 10-4 < P < 0.05) were observed between leukocyte telomere length (LTL) with all glioma (ORSD = 3.91, P = 9.24 × 10-3) and GBM (ORSD = 4.86, P = 3.23 × 10-2), but the association was primarily driven by the TERT variant rs2736100. Serum low-density lipoprotein cholesterol and plasma HbA1C showed suggestive associations with glioma (ORSD = 1.11, P = 1.39 × 10-2 and ORSD = 1.28, P = 1.73 × 10-2, respectively), both associations being reliant on single genetic variants.
CONCLUSIONS: Our study provides further insight into the aetiological basis of glioma for which published data have been mixed.

Entities:  

Year:  2020        PMID: 33020596      PMCID: PMC7852872          DOI: 10.1038/s41416-020-01083-1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  47 in total

1.  Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study.

Authors:  Michael Edlinger; Susanne Strohmaier; Håkan Jonsson; Tone Bjørge; Jonas Manjer; Wegene T Borena; Christel Häggström; Anders Engeland; Steinar Tretli; Hans Concin; Gabriele Nagel; Randi Selmer; Dorthe Johansen; Tanja Stocks; Göran Hallmans; Pär Stattin; Hanno Ulmer
Journal:  J Hypertens       Date:  2012-02       Impact factor: 4.844

2.  The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium.

Authors:  E Susan Amirian; Georgina N Armstrong; Renke Zhou; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Michael E Scheurer; Kenneth Aldape; Irina Alafuzoff; Thomas Brännström; Helle Broholm; Peter Collins; Caterina Giannini; Marc Rosenblum; Tarik Tihan; Beatrice S Melin; Melissa L Bondy
Journal:  Am J Epidemiol       Date:  2015-12-10       Impact factor: 4.897

3.  The INTERPHONE study: design, epidemiological methods, and description of the study population.

Authors:  Elisabeth Cardis; Lesley Richardson; Isabelle Deltour; Bruce Armstrong; Maria Feychting; Christoffer Johansen; Monique Kilkenny; Patricia McKinney; Baruch Modan; Siegal Sadetzki; Joachim Schüz; Anthony Swerdlow; Martine Vrijheid; Anssi Auvinen; Gabriele Berg; Maria Blettner; Joseph Bowman; Julianne Brown; Angela Chetrit; Helle Collatz Christensen; Angus Cook; Sarah Hepworth; Graham Giles; Martine Hours; Ivano Iavarone; Avital Jarus-Hakak; Lars Klaeboe; Daniel Krewski; Susanna Lagorio; Stefan Lönn; Simon Mann; Mary McBride; Kenneth Muir; Louise Nadon; Marie-Elise Parent; Neil Pearce; Tiina Salminen; Minouk Schoemaker; Brigitte Schlehofer; Jack Siemiatycki; Masao Taki; Toru Takebayashi; Tore Tynes; Martie van Tongeren; Paolo Vecchia; Joe Wiart; Alistair Woodward; Naohito Yamaguchi
Journal:  Eur J Epidemiol       Date:  2007-07-18       Impact factor: 8.082

4.  Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.

Authors:  Debbie A Lawlor; Roger M Harbord; Jonathan A C Sterne; Nic Timpson; George Davey Smith
Journal:  Stat Med       Date:  2008-04-15       Impact factor: 2.373

5.  Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Authors:  Beatrice S Melin; Jill S Barnholtz-Sloan; Margaret R Wrensch; Christoffer Johansen; Dora Il'yasova; Ben Kinnersley; Quinn T Ostrom; Karim Labreche; Yanwen Chen; Georgina Armstrong; Yanhong Liu; Jeanette E Eckel-Passow; Paul A Decker; Marianne Labussière; Ahmed Idbaih; Khe Hoang-Xuan; Anna-Luisa Di Stefano; Karima Mokhtari; Jean-Yves Delattre; Peter Broderick; Pilar Galan; Konstantinos Gousias; Johannes Schramm; Minouk J Schoemaker; Sarah J Fleming; Stefan Herms; Stefanie Heilmann; Markus M Nöthen; Heinz-Erich Wichmann; Stefan Schreiber; Anthony Swerdlow; Mark Lathrop; Matthias Simon; Marc Sanson; Ulrika Andersson; Preetha Rajaraman; Stephen Chanock; Martha Linet; Zhaoming Wang; Meredith Yeager; John K Wiencke; Helen Hansen; Lucie McCoy; Terri Rice; Matthew L Kosel; Hugues Sicotte; Christopher I Amos; Jonine L Bernstein; Faith Davis; Dan Lachance; Ching Lau; Ryan T Merrell; Joellen Shildkraut; Francis Ali-Osman; Siegal Sadetzki; Michael Scheurer; Sanjay Shete; Rose K Lai; Elizabeth B Claus; Sara H Olson; Robert B Jenkins; Richard S Houlston; Melissa L Bondy
Journal:  Nat Genet       Date:  2017-03-27       Impact factor: 41.307

6.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.

Authors:  Jack Bowden; George Davey Smith; Stephen Burgess
Journal:  Int J Epidemiol       Date:  2015-06-06       Impact factor: 7.196

7.  Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal.

Authors:  T Remen; J Pintos; M Abrahamowicz; J Siemiatycki
Journal:  BMC Cancer       Date:  2018-12-19       Impact factor: 4.430

8.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

9.  MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization.

Authors:  Louise A C Millard; Neil M Davies; Nic J Timpson; Kate Tilling; Peter A Flach; George Davey Smith
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

Review 10.  Evaluating the potential role of pleiotropy in Mendelian randomization studies.

Authors:  Gibran Hemani; Jack Bowden; George Davey Smith
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

View more
  2 in total

Review 1.  Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme.

Authors:  Swastika Maitra; Biswajit Chakraborty; Sumira Malik; Athanasios Alexiou; Nobendu Mukerjee; Subhradeep Roy; Shaswata Modak; Mohammad Mehedi Hasan; Arabinda Ghosh; Asmita Ghosh; Mohammad Amjad Kamal; Abhijit Dey; Ghulam Md Ashraf; Md Habibur Rahman; Badrah S Alghamdi; Adel Mohammad Abuzenadah
Journal:  Metab Brain Dis       Date:  2022-09-23       Impact factor: 3.655

2.  Relationship between genetically determined telomere length and glioma risk.

Authors:  Charlie N Saunders; Ben Kinnersley; Richard Culliford; Alex J Cornish; Philip J Law; Richard S Houlston
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.